title: Hearing thresholds at high frequency in patients with cystic fibrosis: a systematic review.
abstract: BACKGROUND
  High-frequency audiometry may contribute to the early detection of hearing loss caused by ototoxic medications. Many ototoxic drugs are widely used in the treatment of patients with cystic fibrosis. Early detection of hearing loss should allow known harmful drugs to be identified before the damage affects speech frequencies. The damage caused by ototoxicity is irreversible, resulting in important social and psychological consequences. In children, hearing loss, even when restricted to high frequencies, can affect the development of language.
  
  
  OBJECTIVE
  To investigate the efficacy and effectiveness of hearing monitoring through high-frequency audiometry in pediatric patients with cystic fibrosis.
  
  
  METHODS
  Electronic databases PubMed, MedLine, Web of Science and LILACS were searched, from January to November 2015. The selected studies included those in which high-frequency audiometry was performed in patients with cystic fibrosis, undergoing treatment with ototoxic drugs and published in Portuguese, English and Spanish. The GRADE system was chosen for the evaluation of the methodological quality of the articles.
  
  
  RESULTS
  During the search process carried out from January 2015 to November 2015, 512 publications were identified, of which 250 were found in PubMed, 118 in MedLine, 142 in Web of Science and 2 in LILACS. Of these, nine articles were selected.
  
  
  CONCLUSIONS
  The incidence of hearing loss was identified at high frequencies in cystic fibrosis patients without hearing complaints. It is assumed that high-frequency audiometry can be an early diagnostic method to be recommended for hearing investigation of patients at risk of ototoxicity.
authors.affiliation: Universidade Federal do Rio Grande do Sul (UFRGS), Faculdade de Medicina (Famed), Saúde da Criança e do Adolescente, Porto Alegre, RS, Brazil. Electronic address: deboratmc@hotmail.com.
authors.forename: Debora T M
authors.initials: DTM
authors.lastname: Caumo
authors.affiliation: Hospital de Clínicas de Porto Alegre (HCPA), Serviço de Otorrinolaringologia, Porto Alegre, RS, Brazil.
authors.forename: Lúcia B
authors.initials: LB
authors.lastname: Geyer
authors.affiliation: Universidade Federal do Rio Grande do Sul (UFRGS), Instituto de Psicologia, Departamento de Saúde e Comunicação Humana, Porto Alegre, RS, Brazil.
authors.forename: Adriane R
authors.initials: AR
authors.lastname: Teixeira
authors.affiliation: Universidade Federal do Rio Grande do Sul (UFRGS), Faculdade de Medicina (Famed), Departamento de Medicina Interna, Porto Alegre, RS, Brazil.
authors.forename: Sérgio S M
authors.initials: SSM
authors.lastname: Barreto
mesh_terms: D000617:Aminoglycosides / Q000009:adverse effects*; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold; D003550:Cystic Fibrosis / Q000188:drug therapy; D034381:Hearing Loss / Q000139:chemically induced* / Q000175:diagnosis*; D006801:Humans; D017084:Otoacoustic Emissions, Spontaneous
chemical_list: D000617:Aminoglycosides
keywords: Audiometria; Audiometry; Cystic fibrosis; Fibrose cística; Hearing loss; Ototoxicidade; Ototoxicity; Perda auditiva